Condensed Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating activities
Net loss	$ (7,026,424)	$ (4,088,134)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	357,023	151,493
Accretion of discount on NuvoGen obligation	52,082	126,566
Bad debt expense, net of recoveries		(16,146)
Provision for excess inventory	30,542	21,926
Amortization of deferred financing costs	7,431	3,508
Amortization of discount on term loan	51,908	36,520
Amortization of final payment premium on term loan	43,640	24,237
Amortization of discount on convertible notes		32,006
Stock-based compensation expense	170,048	76,548
Change in redeemable convertible preferred stock warrant liability		(388,960)
Amortization of convertible note financing costs		15,107
Accretion of incentive from landlord	(23,666)
Accrued interest on available-for-sale securities investments	(7,288)
Loss on disposal of assets		49,341
Changes in operating assets and liabilities:
Accounts receivable	141,680	(35,014)
Inventory	(195,203)	(431,598)
Prepaid expenses and other	119,538	(10,114)
Accounts payable	714,361	(69,456)
Accrued liabilities	(537,061)	96,544
Deferred revenue	(22,028)	(9,233)
Net cash used in operating activities	(6,123,417)	(4,414,859)
Investing activities
Purchase of property and equipment	(220,570)	(343,703)
Sales, redemptions and maturities of available-for-sale securities	3,000,000
Net cash provided by (used in) investing activities	2,779,430	(343,703)
Financing activities
Proceeds from exercise of stock options		4,972
Proceeds from exercise of E warrants		7,196
Deferred offering costs		(219,908)
Deferred convertible note financing costs		(75,535)
Payments on capital leases	(27,300)	(7,311)
Proceeds from term loan	5,000,000
Proceeds from issuance of convertible note warrants		3,000,000
Net cash provided by financing activities	4,972,700	2,709,414
Increase (decrease) in cash and cash equivalents	1,628,713	(2,049,148)
Cash and cash equivalents at beginning of period	3,293,983	3,613,392
Cash and cash equivalents at end of period	4,922,696	1,564,244
Noncash investing and financing activities
Accretion of preferred stock issuance costs		24,077
Accretion of dividends		798,582
Accrual of deferred offering and finance costs		96,598
Allocation of Series E warrant convertible notes debt discount		741,828
Allocation of term loan B warrant discount	122,460
Fixed asset purchases payable and accrued for payment at period end	1,030,174
Stock issued for payment of 2015 annual bonus	(364,910)
Purchase of property and equipment under capital lease	176,360
Incentive from landlord	710,000
Supplemental cash flow information
Cash paid for interest	$ 237,397	233,750
Series D And E Redeemable Convertible Preferred Stock
Noncash investing and financing activities
Accretion of dividends		798,582
Series E Warrants
Noncash investing and financing activities
Exercise of warrants		(4,116)
Accretion of warrant discount		$ 87,470